These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14581894)

  • 1. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution.
    Simon GR; Ruckdeschel JC; Williams C; Cantor A; Chiappori A; Rocha Lima CM; Antonia S; Haura E; Wagner H; Robinson L; Sommers E; Alberts M; Bepler G
    Cancer Control; 2003; 10(5):388-95. PubMed ID: 14581894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
    Fukuoka M; Yano S; Giaccone G; Tamura T; Nakagawa K; Douillard JY; Nishiwaki Y; Vansteenkiste J; Kudoh S; Rischin D; Eek R; Horai T; Noda K; Takata I; Smit E; Averbuch S; Macleod A; Feyereislova A; Dong RP; Baselga J
    J Clin Oncol; 2003 Jun; 21(12):2237-46. PubMed ID: 12748244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
    Santoro A; Cavina R; Latteri F; Zucali PA; Ginanni V; Campagnoli E; Ferrari B; Morenghi E; Pedicini V; Roncalli M; Alloisio M; Ravasi G; Soto Parra HJ
    Ann Oncol; 2004 Jan; 15(1):33-7. PubMed ID: 14679116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
    Pallis AG; Mavroudis D; Androulakis N; Souglakos J; Kouroussis C; Bozionelou V; Vlachonikolis IG; Georgoulias V
    Lung Cancer; 2003 Jun; 40(3):301-7. PubMed ID: 12781429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
    Veronese ML; Algazy K; Bearn L; Eaby B; Alavi J; Evans T; Stevenson JP; Shults J
    Cancer Invest; 2005; 23(4):296-302. PubMed ID: 16100941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Argiris A; Mittal N
    Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
    Chang GC; Tsai CM; Chen KC; Yu CJ; Shih JY; Yang TY; Lin CP; Hsu JY; Chiu CH; Perng RP; Yang PC; Yang CH
    J Thorac Oncol; 2006 Jul; 1(6):520-5. PubMed ID: 17409911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib monotherapy in advanced non-small-cell lung cancer: a retrospective analysis.
    Shrestha S; Joshi P
    JNMA J Nepal Med Assoc; 2012; 52(186):66-71. PubMed ID: 23478732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
    Lee YJ; Kim HT; Han JY; Yun T; Lee GK; Kim HY; Sung JH; Lee JS
    J Thorac Oncol; 2010 Mar; 5(3):361-8. PubMed ID: 20107420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
    J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
    Zhang Y; Zhang L; Xu F; Wang ZQ; Zhao HY; Guan ZZ; Xu GC; Pan ZK
    Ai Zheng; 2006 Dec; 25(12):1561-4. PubMed ID: 17166387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
    Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
    J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.
    Xu JM; Han Y; Li YM; Zhao CH; Wang Y; Paradiso A
    BMC Cancer; 2006 Dec; 6():288. PubMed ID: 17173694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
    van Puijenbroek R; Bosquée L; Meert AP; Schallier D; Goeminne JC; Tits G; Collard P; Nackaerts K; Canon JL; Duplaquet F; Galdermans D; Germonpré P; Azerad MA; Vandenhoven G; De Greve J; Vansteenkiste J
    Eur Respir J; 2007 Jan; 29(1):128-33. PubMed ID: 17005582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status.
    Chang GC; Chen KC; Yang TY; Yin MC; Lin CP; Kuo BI; Hsu JY
    Invest New Drugs; 2005 Jan; 23(1):73-7. PubMed ID: 15528983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
    Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
    Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
    Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.